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Abstract 
 Lamivudine monoprophylaxis against hepatitis B virus (HBV) reinfection after liver 
transplantation is associated with recurrence due to escape mutants and second generation 
recombinant HBV vaccine is not effective.  We studied the efficacy of 2 courses each of 3 
double-doses (20 ug) of third generation recombinant pre-S containing vaccine (Sci-B-VacTM) in 
20 patients on lamivudine prophylaxis at a median of 637 days (range, 390-2,666 days) after 
transplantation. At enrolment, all patients were seronegative for HBsAg, anti-HBs and 
HBVDNA (by qPCR). Lamivudine (100 mg/day) was continued throughout the study.  Five 
patients (25%) responded to the first course and 5 additional patients responded after the second 
course (overall response rate 50%). The response rate was 88% in patients younger than 50 years 
old and 25% in older patients (p=0.02). The median peak anti-HBs titer was 153 mIU/mL with 6 
responders having a titer > 100 mIU/mL and 7 sustained > 6 months.  Among 7 previous non-
responders to second generation recombinant vaccine, 3 (44%) responded.  At the end of the 
study, all patients remained seronegative for HBsAg.  In conclusion, Sci-B-VacTM is effective in 
about 50% of patients receiving lamividine prophylaxis and may prevent recurrence due to 
escape mutants. 
Keywords: Active immunization; Immunity; Recurrence; Antibody against hepatitis B 
surface antigen 
Word count for Abstract: 198 words 
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1. Introduction 
 The results of liver transplantation for hepatitis B virus (HBV)-related liver disease has 
dramatically improved over the last decade. Passive immunoprophylaxis with hepatitis B 
immunoglobulin (HBIG) (1,2) and anti-viral agents such as lamivudine (3,4,5) are both effective 
in preventing HBV reinfection after liver transplantation. The graft survival with lamivudine 
monoprophylaxis is comparable to that of long-term HBIG prophylaxis (4) but reinfection due to 
emergence of escape mutant with prolonged therapy is the major concern. Combining HBIG 
with lamivudine prophylaxis has proved to be extremely effective in reducing HBV reinfection 
to less than 10% (6-12) and this combination has been regarded by many as the preferred 
prophylactic strategy (13). Nonetheless, the potential drawbacks of long-term HBIG continues to 
be an issue and the optimal dosage and duration of HBIG therapy remain unknown. Hence, 
attempts to develop less costly and more definitive means of prophylaxis against HBV 
reinfection continue.  
 
 Vaccination to confer active immunity for endogenous production of anti-HBs is 
theoretically a simpler, safer and cheaper prophylactic strategy than passive immunization using 
HBIG. We have previously proposed a strategy of combining active immunization with antiviral 
prophylaxis, and attempted HBV vaccination as an additional prophylactic measure to reduce the 
risk of emergence of escape mutants in patients receiving lamivudine prophylaxis after liver 
transplantation (14). Unfortunately, 2 courses of an accelerated schedule of double-dose second-
generation recombinant HBV vaccine had limited efficacy in this setting. In this study, we 
continue to explore this strategy and evaluated the efficacy of a more immunogenic third-
generation recombinant HBV vaccine containing S, pre-S1 and pre-S2 antigens.  
 
2. Patients and methods 
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Patients 
 Twenty liver transplant recipients who had undergone liver transplantation for chronic 
hepatitis B-related liver disease and had no evidence of HBV recurrence nor immunity at more 
than 12 months after transplantation were recruited at the outpatient clinic into the current study. 
The baseline demographic, clinical and virologic characteristics of these patients are shown in 
Table 1. There were 15 men and 5 women with a mean age of 50.8 years (median, 52 years; 
range, 35-60 years). The disease indication for transplantation was decompensated cirrhosis in 18 
patients and cirrhosis with acute flare in 2 patients. Serum HBV DNA was positive by a 
branched-chain DNA (bDNA) assay (Quantiplex; Chiron Diagnostics, Emeryville, CA; lowest 
detection limit, 700,000 copies/mL) in 6 patients on listing and in 4 patients at transplantation. 
None had coinfection with hepatitis delta virus or hepatitis C virus.  Two patients had received 
lamivudine therapy (100 mg daily) for more than 12 months before transplantation and 8 for 1 
month to 12 months. The remaining 10 patients had pretransplant lamivudine for less than 1 
month. Lamivudine therapy was continued indefinitely after transplantation according to a 
protocol as described previously (5) and HBIG was not used at any stage.  
 
We excluded patients who had received the transplant for less than 12 months, who had 
received other prophylaxis such as passive immunoprophylaxis with HBIG or add-on adefovir 
dipivoxil therapy, who were HBsAg-positive with or without viral breakthrough, or who 
remained positive for anti-HBs after transplantation. The median interval from transplantation to 
enrolment was 637 days (range, 390 to 2666 days). Thirteen (65%) patients had received liver 
transplant for 1-3 years and 7 (35 %) had the transplant more than 3 years ago. Eight patients had 
previously been enrolled in a study on vaccination using two courses of a double-dose reinforced 
schedule of second generation recombinant HBV vaccine (14). Seven did not respond and only 
one developed a peak anti-HBs titer of 27 mIU/mL that disappeared rapidly. The last dose of 
   Lo    HBV vaccination and lamivudine prophylaxis 
                                                                                        AJT-O-06-00718 
5
vaccination was administered no less than 18 months before entry into the current study and the 
serum anti-HBs had remained negative for at least 6 months. At the time of enrolment into the 
current study, all 20 patients had negative serology for HBsAg, anti-HBs, and HBV DNA by 
qPCR assay (Cobas Amplicor qPCR, Roche Molecular Diagnostics, Branchburg, NJ; lowest 
detection limit 300 copies/mL). Graft functions were normal and there were no significant 
posttransplant complications. Immunosuppressive medications consisted of tacrolimus alone in 
16 patients, tacrolimus with steroid and mycophenolate mofetil in 2 patients, tacrolimus with 
mycophenolate, and steroid alone in one patient each. 
 
Vaccination protocol  
 Patients enrolled in the study received a third generation recombinant hepatitis B vaccine 
(Sci-B-VacTM, Bio-Technology General Ltd., Rehovot, Israel) produced in HBV transfected 
Chinese hamster ovary cells  which secretes  all 3 epitopes of the envelope proteins, namely S, 
pre-S1 and pre-S2.  The schedule consisted of 2 courses each of 3 double-doses (20 μg) of 
vaccine administered by intramuscular injection into deltoid muscle at months 0, 1, and 2 and 
then months 6, 7, and 8 after enrolment.  
 
Follow-up and response 
The patients were followed at least monthly at the clinic and the anti-HBs titer was 
measured using a microparticle enzyme immunoassay (IMx AUSAB, Abbott Laboratories, 
Chicago, IL) before each dose of vaccine, and monthly for at least 6 months after the last dose of 
vaccine. The primary outcome was the development of anti-HBs, and a titer greater than 10 
mIU/ml was considered a positive response. A positive response that persisted at 6 months after 
the last dose of vaccine was considered a sustained response. Patients who responded after the 
first course of vaccine were regarded as early responders. Hematological and biochemical 
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parameters were tested at each study visit. Recurrent disease was monitored by hepatitis B 
serologies including serum HBsAg (Auszyme Monoclonal EIA; Abbott Laboratories, Chicago, 
IL), HBeAg (Axsym HBe 2 MEIA; Abbott Laboratories), and HBV DNA (Cobas Amplicor 
qPCR) at 3 monthly intervals throughout the study period and when clinically indicated. The 
study protocol was approved by the institutional review board and informed consent was 
obtained from each patient.  
 
3. Results 
Response to vaccination 
 Upon completion of the first course of vaccination, 5 patients had positive response 
(median anti-HBs titer, 34 mIU/mL; range 14 to 66 mIU/mL) giving an early response rate of 
25%. The only patient who had previously responded to second generation recombinant vaccine 
had an early response after the first course (peak anti-HBs titer of 66 mIU/mL) but he did not 
comply with the schedule of the second course. Hence, 19 patients received the second course of 
vaccination and 5 additional patients developed anti-HBs afterward. Hence, the overall response 
rate in these 20 patients was 50%. The median peak anti-HBs titer was 153 mIU/mL (range, 13 
to >1000 mIU/mL) with 7 of the responders (70%) having a maximum titer > 100 mIU/mL, 
including 2 (20%) > 1,000 mIU/mL.  
 The demographic, clinical and virologic data of the responders and non-responders were 
compared in Table 2. Response to HBV vaccine was not related to the pretransplant HBV 
serology, duration of lamivudine treatment, donor anti-HBs status, use of living donor graft, 
interval since transplantation or previous HBV vaccination but was associated with a younger 
age. A positive response was found in 7 of  8 patients (88%) younger than 50 years of age as 
compared to 3 of 12 (25%) older patients (p=0.02). Among the 7 patients who had previously not 
responded to second-generation recombinant HBV vaccine, 3 (44%) responded to the vaccine in 
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the current study. The only patient who had previously responded to the second generation 
recombinant vaccine responded again in this study.  
   
Follow-up 
 None of the patients reported any side effects related to the vaccination. The serial 
changes in the anti-HBs titers of the 10 responders are shown in the figure. Sustained response 
beyond 6 months after the completion of the second course of vaccination was found in 7 of the 
9 responders (one early responder did not receive the second course). All 4 early responders 
responded to the second course with a rapid rise in anti-HBs titer to > 100 mIU/mL (median peak 
titer 317 mIU/mL; range 100 to >1000 mIU/mL) and all had sustained response.  Five of 15 early 
non-responders developed a response to the second course of vaccine (median peak titer 20 
mIU/mL; range 13 to >1000 mIU/mL) with an anti-HBs titer > 100 mIU/mL in 2 patients and 
only 3 had sustained response. All the study patients continued to receive lamivudine 100 mg 
daily. As on the date of the latest follow up (median, 55 months; range, 47-111 months after 
transplantation), none of the 20 patients developed recurrence and all were negative for HBsAg, 
HBeAg, and HBV DNA (by qPCR). Four patients remained positive for anti-HBs with a median 
titre of 55 mIU/mL (range 42 to 135 mIU/mL) at 33 months after vaccination.  
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4. Discussion 
 Recurrence due to emergence of escape mutant is common with long-term lamivudine 
prophylaxis after liver transplantation (3,4) and additional prophylactic measure such as passive 
immunoprophylaxis has been recommended. On the other hand, lamivudine-resistant HBV 
mutant can now be effectively controlled with other anti-viral agents such as adefovir dipivoxil 
(15,16). As a result of the prohibitive cost of HBIG, we have adopted a strategy of anti viral 
prophylaxis using primary lamivudine with adefovir rescue with fairly good results in terms of 
graft and patient survival (16). A recent study indicated that the cost-effectiveness of 
combination of lamivudine and HBIG is highly sensitive to the cost of HBIG (17) and when 
compared to a strategy of lamivudine with adefovir rescue, the incremental cost-effectiveness 
ratio of lamivudine with HBIG exceeds the threshold for cost-effectiveness even when a regimen 
of very low dose intramuscular HBIG was considered. Antiviral prophylaxis using lamivudine 
with adefovir rescue was found to be the more cost-effective option, though at a possible price of 
higher recurrence rate.  
 
 The current study shows that a strategy of combining active immunization to reduce the 
recurrence rate with anti-viral prophylaxis is feasible in a proportion of patients after liver 
transplantation for chronic hepatitis B. About half of post-transplant patients receiving 
lamivudine prophylaxis responded to 2 courses of a more immunogenic third-generation pre-S 
containing HBV vaccine, Sci-B-VacTM. In a significant proportion of the responders, the ani-
HBs titer was higher than 100 mIU/mL and the response was sustained for more than 6 months. 
All early responders who responded to the first course had intense and sustained antibody 
response after the second course suggesting that a second course of vaccination is necessary 
and should be given even in the early responders. Whether additional courses of vaccine or 
boosters would enhance or prolong the humoral immune response remains to be defined by 
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further studies. Admittedly, the follow up period of the current study is relatively short and 
we assessed immunogenicity of the vaccine instead of its efficacy to prevent recurrence. 
Nonetheless, this is the first report of the successful induction of active humoral immune 
response in a sizable proportion of patients on lamivudine prophylaxis after transplantation. 
Anti-HBs response is protective against HBV infection and is likely to offer protection against 
the emergence of lamivudine-resistant mutant which is the major drawback of long term anti-
viral monoprophylaxis. The ultimate objective of this strategy, however, is to provide definitive 
protection against HBV reinfection. Before lamivudine prophylaxis can be discontinued, more 
studies are needed to provide proof on the complete clearance of HBV and the durability of the 
HBV immune response. 
 
 The results of the present study contrasted with our previous report in which 2 courses of 
a second-generation recombinant vaccine failed to induce active immunity in a similar setting 
(14). In fact, 44% of previous non-responders in the last study responded to Sci-B-VacTM, hence, 
confirming the enhanced immunogenicity of the third-generation vaccine. The vaccine contains 
glycosylated and nonglycosylated forms of all 3 epitopes of the envelope proteins absorbed to 
alum and has been shown to have an immunogenic advantage by eliciting a faster and more 
intense antibody response (18,19) as well as a superior response rate in non-responders of 
second-generation yeast-derived vaccine (20).  
 
 The question remains open why some patients respond to Sci-B-VacTM while others do 
not. The response to vaccination was not related to the donor’s HBV immunity status and 
was unlikely to be a secondary response of the adoptively transferred immunity from an HBV 
immune donor (21). The relatively small number of study subjects limited the power of the 
current study but age was found to be a predictor of response and this is compatible with 
   Lo    HBV vaccination and lamivudine prophylaxis 
                                                                                        AJT-O-06-00718 
10
previous findings on the effect of age on response to HBV vaccination in non-transplant 
setting (22,23). The favorable response rate of 88% in patients younger than 50 years of age 
in the current study indicates that these patients are likely to benefit from the vaccination and 
should receive at least 2 courses of the vaccine. For patients who were older, the response 
rate was low (25%) and an early non-response to the first course of vaccination would be 
predictive of a failure of active immunization.  
 
 Reported trials of active immunization to replace HBIG in patients receiving passive 
immunoprophylaxis included only patients who were at low risk for HBV reinfection based 
on a pretransplant non-replicative HBV status and a prolonged post-transplant recurrence-
free period (24-27). On the other hand, the value of prevention depends on the risk of an 
event and the cost-effectiveness of any prophylactic measure against HBV refection increases 
with the risk of recurrence. Hence, in order to investigate the value of vaccination as an 
additional measure to prevent the emergence of lamivudine-resistant mutant, we did not 
exclude high-risk patients with active HBV replication before transplant who were most 
likely to benefit from the additional protection. All patients in the current study suffered from 
chronic HBV-related cirrhosis and none had fulminant hepatitis B or coinfection with 
hepatitis delta virus. Active HBV replication as indicated by a positive serum HBV DNA by 
bDNA assay (lowest detection limit 0.7 x 106 copies/ml) was present in 6 patients on listing 
and in 4 patients before transplantation. Since the risk of recurrence increases rapidly with 
prolonged therapy, the vaccination should ideally be initiated as early as possible just before 
the surge of escape mutants. Nonetheless, in contrast to most patients receiving HBIG who 
have no detectable HBsAg in serum within a few days after transplantation, serum HBsAg 
may remain positive initially in many patients receiving lamivudine monoprophylaxis, 
progressively declining over a period of several months to become undetectable. Furthermore, 
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we have previously observed that about 40% of our patients on lamivudine prophylaxis 
developed anti-HBs spontaneously after transplantation which lasted for a median of about 7 
months (21). As a result of such distinct post-transplant serologic profile, the optimal time for 
active immunization for these patients would probably be at one year after transplant. It 
would be necessary to conduct a prospective study in which active immunization is included 
as part of the protocol for prophylaxis for all patients who are at risk. 
 
 In conclusion, 2 courses of double-dose third-generation recombinant pre-S containing 
HBV vaccine induce humural immune response in selected patients receiving lamivudine 
prophylaxis after liver transplantation. The additional protection may prevent the emergence of 
escape mutants and improve further the outcome of the strategy of lamivudine prophylaxis with 
adefovir rescue. More studies should be performed to identify the patients who would benefit 
most from active immunization and to increase the response rate by defining the optimal 
schedule and timing of vaccination. 
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Figure legend 
Serial changes in anti-HBs titers after vaccination in 10 responders. 
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Table 1 Demographic, clinical and virologic characteristics of study patients 
 
Disease indication On listing 
___________________
Pre-LTx 
___________________
Pretransplant 
lamivudine 
(days) 
Graft 
type  
Response to 
previous 
HBV vaccine
Patient no. Gender/Age
 HBeAg   HBV DNA* HBeAg   HBV DNA*   
Donor  
anti-HBs
 
Interval since 
LTx (days) 
Immunosuppression 
at enrolment 
1 M/60 Cirrhosis -        - -        - 245 Deceased n/a - 2302 Steroid 
2 
 
M/53 Cirrhosis -        - -        1.54 63 Live  + Not done 498 Tac 
3 
 
F/57 Cirrhosis +        - +        - 2 Live - Not done 477 Tac 
4 
 
F/52 Cirrhosis -        - -        - 0 Live - Not done 522 Tac 
5 M/60 Cirrhosis -                     2.436 -                      - 197 Deceased + Not done 440 Steroid, Tac, MMF 
6 M/55 Cirrhosis -                     - -                     - 193  + Not done 562 Tac 
7 M/46 Cirrhosis -                     - -                     - 1 Deceased + Not done 1757 Tac 
8 F/53 Cirrhosis -                     - -                     - 46 Deceased - Not done 527 Tac 
9 M55 Cirrhosis -                     1.652 -                     - 560 Live + - 984 Tac 
10 M56 Cirrhosis -                     - -                     - 45 Live + - 1166 Tac 
11 M/45 Cirrhosis with acute 
flare 
+                    - -                     - 25 Live + - 1069 Tac 
12 F/36 Cirrhosis with acute 
flare 
-                    - -                     - 6 Deceased + Not done 563 Tac 
13 M/47 Cirrhosis +                   - -                     - 134 Deceased - Not done 390 Tac 
14 M/48 Cirrhosis -                   - -                     - 45 Live + - 1617 Tac 
15 F/60 Cirrhosis +                  2.8 +                   2.8 0 Live - Not done 573 Tac 
16 M/52 Cirrhosis -                   2.576 -                    2.576 5 Live + Not done 443 Tac, MMF 
17 M/50 Cirrhosis -                   - -                     - 20 Live + - 1143 Steroid, Tac, MMF 
18 M/46 Cirrhosis +                  176.4 +                   1.4 22 Live - - 1599 Tac 
19 M/35 Cirrhosis -                   8.68  -                    - 566 Deceased + Not done 701 Tac 
20 M/49 Cirrhosis +                  -  -                     - 4 Live + + 2666 Tac 
LTx, liver transplantation; HBV, hepatitis B virus; -, negative; +, positive; n/a, not available; Tac, Tacrolimus; MMF, mycophanolate mofetil. 
* by bDNA assay (x 106 copies/ml; lowest detection limit, 0.7 x 106 copies/ml).
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Table 2 Comparison of demographic, clinical and virologic data of responders and non-
responders 
 
 Responder 
(n=10) 
Non-responder 
(n=10) 
Male gender 
 
8 7 
Age in years, median (range) 
 
47.5 (36-57) 
 
54(35-60)* 
 
Age < 50 years 
 
7 1# 
HBeAg positive 
 on listing 
 at transplantation 
 
 
5 
2 
 
1 
1 
HBVDNA positive 
 on listing 
 at transplantation 
 
 
1 
2 
 
5 
2 
Disease indication 
 Cirrhosis 
 Cirrhosis with acute flare 
 
 
8 
2 
 
10 
0 
Duration of lamivudine pretransplant 
 < 1 month 
 1 month – 1 year 
 > 1 year 
 
 
6 
4 
0 
 
4 
4 
2 
Donor anti-HBs+ 
 
7 6 
Living donor graft 
 
7 6 
Interval since transplantation 
 1 – 3 years 
 > 3 years 
 
 
6 
4 
 
7 
3 
Previous HBV vaccination 
 
4 4 
 
*P = 0.05 
#P = 0.02 
 
 
 
 
 
